1. miR-99b-5p, miR-380-3p, and miR-485-3p are novel chemosensitizing miRNAs in high-risk neuroblastoma
- Author
-
Holliday, H, Yang, J, Dodson, E, Nikolic, I, Kamili, A, Wheatley, M, Deng, N, Alexandrou, S, Davis, TP, Kavallaris, M, Caldon, CE, McCarroll, J, De Preter, K, Mestdagh, P, Marshall, GM, Simpson, KJ, Fletcher, J, Swarbrick, A, Holliday, H, Yang, J, Dodson, E, Nikolic, I, Kamili, A, Wheatley, M, Deng, N, Alexandrou, S, Davis, TP, Kavallaris, M, Caldon, CE, McCarroll, J, De Preter, K, Mestdagh, P, Marshall, GM, Simpson, KJ, Fletcher, J, and Swarbrick, A
- Abstract
Neuroblastoma is a deadly childhood cancer arising in the developing sympathetic nervous system. High-risk patients are currently treated with intensive chemotherapy, which is curative in only 50% of children and leaves some surviving patients with life-long side effects. microRNAs (miRNAs) are critical regulators of neural crest development and are deregulated during neuroblastoma tumorigenesis, making miRNA-based drugs an attractive therapeutic avenue. A functional screen of >1,200 miRNA mimics was conducted in neuroblastoma cell lines to discover miRNAs that sensitized cells to low doses (30% inhibitory concentration [IC30]) of doxorubicin and vincristine chemotherapy used in the treatment of the disease. Three miRNAs, miR-99b-5p, miR-380-3p, and miR-485-3p, had potent chemosensitizing activity with doxorubicin in multiple models of high-risk neuroblastoma. These miRNAs underwent genomic loss in a subset of neuroblastoma patients, and low expression predicted poor survival outcome. In vitro functional assays revealed each of these miRNAs enhanced the anti-proliferative and pro-apoptotic effects of doxorubicin. We used RNA sequencing (RNA-seq) to show that miR-99b-5p represses neuroblastoma dependency genes LIN28B and PHOX2B both in vitro and in patient-derived xenograft (PDX) tumors. Luciferase reporter assays demonstrate that PHOX2B is a direct target of miR-99b-5p. We anticipate that restoring the function of the tumor-suppressive miRNAs discovered here may be a valuable therapeutic strategy for the treatment of neuroblastoma patients.
- Published
- 2022